Press Releases NexImmune, Inc.

Equities

NEXI

US65344D2080

Market Closed - Nasdaq Other stock markets 03:59:53 2024-06-14 pm EDT			5-day change	1st Jan Change
2.95 ^USD	+1.72%		-1.67%	+32.88%

May. 20	NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Feb. 02	AQ
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	Jan. 08	AQ
Neximmune : Failure to Satisfy Listing Rule - Form 8-K	Dec. 01	PU
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	23-10-24	AQ
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting	23-10-19	GL
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting	23-10-19	AQ
NexImmune Announces 1-for-25 Reverse Stock Split	23-10-18	GL
NexImmune Announces 1-for-25 Reverse Stock Split	23-10-18	AQ
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy	23-08-31	GL
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy	23-08-31	AQ
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates	23-08-10	GL
NexImmune : Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Form 8-K	23-06-05	PU
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting	23-06-05	AQ
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting	23-05-22	AQ
NEXIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-15	AQ
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates	23-05-15	GL
NEXIMMUNE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events (form 8-K)	23-04-26	AQ
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting	23-04-26	AQ
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-28	AQ
NEXIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-03-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NexImmune, Inc.

Equities

NEXI

US65344D2080

Press Releases

Filters